Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
24.92
+0.64 (2.64%)
At close: Dec 20, 2024, 4:00 PM
25.01
+0.09 (0.36%)
After-hours: Dec 20, 2024, 5:31 PM EST

Royalty Pharma Revenue

Royalty Pharma had revenue of $564.69M in the quarter ending September 30, 2024, with 5.29% growth. This brings the company's revenue in the last twelve months to $2.27B, down -2.51% year-over-year. In the year 2023, Royalty Pharma had annual revenue of $2.35B with 5.24% growth.

Revenue (ttm)
$2.27B
Revenue Growth
-2.51%
P/S Ratio
4.93
Revenue / Employee
$25,460,708
Employees
89
Market Cap
14.68B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20232.35B117.34M5.24%
Dec 31, 20222.24B-52.25M-2.28%
Dec 31, 20212.29B167.11M7.87%
Dec 31, 20202.12B308.10M16.98%
Dec 31, 20191.81B19.36M1.08%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Fresenius Medical Care AG 21.46B
Baxter International 15.06B
Viatris 15.05B
Avantor 6.82B
Moderna 5.08B
Align Technology 3.96B
United Therapeutics 2.76B
Revvity 2.72B
Revenue Rankings